Search Results

The GPCR Data Dilemma: The Lego Bucket Problem I've seen promising GPCR programs generate massive volumes Systems That Drive Progress:  From assay tracking to data workflows, I design simple, scalable tools GPCR As the co-founder of Dr. GPCR, we've built a global hub connecting over 1,300 GPCR scientists dedicated to this field. Ready to Move Your GPCR Program Forward?

This partnership is designed to support the GPCR research community by expanding access to validated, Eurofins DiscoverX assay solutions are used throughout GPCR drug discovery workflows, from target identification GPCR and Eurofins DiscoverX aim to accelerate GPCR-targeted drug discovery by connecting scientists with platforms, deep pharmacological expertise, and expert-driven context that supports better experimental design GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.

Read the article now ➤ Discovery on Target - The Next Wave of GPCR Drug Discovery The 20th Annual GPCR-Based Drug Discovery Conference  isn’t just another event—it’s where the frameworks shaping the next decade GPCR Premium Membership Gives You an Edge The GPCR field is advancing at breakneck speed. The pace of GPCR innovation is accelerating. Aside from his vast experience in drug development, not to mention his extensive publication record,

GPCR University Masterclass — Integrated GPCR Discovery in Practice Dr. GPCR Masterclass ➤ Eurofins DiscoverX Partnership — Tools and Insight for GPCR Drug Discovery Modern Industry-grade tools signal maturation of GPCR drug discovery. 👉 Read the Partnership Announcement ➤ GPCR Premium Membership Gives You an Edge GPCR drug discovery is accelerating — across obesity, CNS, GPCR operates as a membership-based, nonprofit initiative — built to strengthen the GPCR field through

content — designed to keep you ahead without noise or delays: Industry insights:  Structure-Based Drug Design Summit; AI-Powered GPCR Research; Lab-in-the-Loop Hit Discovery advances. Must-read publications:  GPCRchimeraDB: Database of engineered GPCR designs. lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—all designed GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions

GPCR is proud to partner with the 5th Annual GPCRs-Targeted Drug Discovery Summit. New structural tools, AI-driven design pipelines, and a growing number of programs moving into the clinic biology, structural biology, computational design, pharmacology, and translational strategy. design. primers on AI — they're teams presenting real workflows and real data, covering generative antibody design

safety, efficacy, and design decisions. the next generation of GPCR ligands? You’re not just designing for receptor activity—you’re designing for enzyme survival. Kenakin live for an open Q&A session designed for discovery scientists. design.

Innovative design approach emphasizing scientific principles over speculation. GPCR News delivers a toolkit of practical innovations—from drug design strategies that anticipate physiological Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail GPCR , our mission is simple but urgent: Accelerate GPCR biology and drug discovery by connecting scientists field 🧠 Designed for researchers at every career stage

Strong GPCR drug discovery decisions are built on structure, early risk awareness, and focused signal Each piece is designed to help you make better decisions—faster. 🔍 This Week in Premium: Sneak Peek Upcoming events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug It is operational pharmacology designed to prevent avoidable setbacks. courses and three live AMAs covering binding, kinetics, efficacy, mechanism, ADME, and experimental design

Why GPCR Drug Discovery Is More Complex Than It Looks G protein-coupled receptors (GPCRs) have long occupied Ligands designed to activate therapeutically beneficial pathways, while avoiding those associated with side effects, are no longer a theoretical aspiration — they are an active design objective. design and immediate drug discovery  relevance. , cAMP, and calcium mobilization assays designed specifically to resolve these distinctions and support

In the high-stakes world of GPCR drug discovery , breakthrough science isn't enough. GPCR, we recognized this core problem. The Role of Systems Thinking in GPCR Drug Discovery Systems thinking is the intentional practice of seeing I'll show you how to transform your drug discovery process from a series of disconnected efforts into The GPCR Precision Blueprint is more than a concept.

Why Speed Matters in GPCR Drug Discovery Nine out of ten GPCR programs stall  not because the target Screening technologies, structure-informed design, and AI are accelerating target selection. Terry’s Corner is designed to shorten that distance between initial promise and actionable clarity. This expands the strategic toolbox for discovery teams: Bias isn’t an “optional property” to design in design.

Terry's Corner : Unlock the Power of Intracellular GPCR Drugs For years, GPCR drug discovery has focused GPCR Podcast : The Future of GPCR Drug Discovery with Molecular Modeling The field of GPCR research is This research topic is designed to stimulate discussion and fuel the scientific direction of future GPCR , classified industry news, priority event alerts, job opportunities, and insider commentary—designed GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

Drugs Change the Game For decades, drug design has treated GPCRs as surface targets. You get longer activity with shorter exposure—a dream scenario for drug designers. how this plays out in model systems and clinical data—and why residence time should be a first-class design He also reviews key scaffold properties that determine success, offering practical tips for design teams And while orthosteric ligands may never reach them, properly designed intracellular drugs can.

Over 30% of FDA-approved drugs target GPCRs, with many targeting CNS located GPCRs. key in drug design. Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Both orphan and well-characterized GPCRs are untapped opportunities for drug development targeting CNS Advantages of Fluorescent Ligands in GPCR Drug Screening for CNS Choosing the right tools is important

with built-in selectivity and context sensitivity Why GPCR Allosteric Thinking Changes the Game in Drug Unexpected activity profiles, SAR that breaks your QSAR model, and missed opportunities to design more This has direct implications for: Assay timing and readout design Misclassification of lead candidates But without understanding how GPCR state changes  influence that affinity—or vice versa—drug discovery modulators, the principles in this lecture equip you to design ligands that not only bind, but bind

A Specific Difficulty, Not a General Verdict A pharmacologist designing an orthosteric small-molecule What GPCR Biologic Drugs Reveal About the Active-State Problem Family B GPCRs are conformationally malleable GPCR biologic drugs, peptides in particular, achieve this through a mechanism worth naming carefully. The orthosteric site at a family B GPCR is not closed to small molecules. biologic drugs inherit, and the trafficking decisions that determine receptor fate inside the cell.

In GPCR drug discovery, a single mistaken assumption can derail an entire program. Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you Monthly Ask‑Me‑Anything sessions with live Q&A An expanding on‑demand library for novices to expert drug hunters Influence over upcoming topics Who it’s for:  drug discovery teams, pharmacologists refining Why now:  GPCR research is accelerating—and the projects that succeed will be those built on clear, accurate

GPCR research requires turning data into insights for drug discovery Hi GPCR Friends, Every week, critical drug strategies shifting; antibody pharmacology opening fresh doors. Terry's Corner – Curve Shifts Don’t Lie, But Your Eyes Might In early drug discovery, “those curves look Understand how AI/ML and GPCR biology meet to unlock safer drugs. lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—designed

Design for translation:  Map sensitivity ranges to tissue contexts so your plate data predicts what happens Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters drug discovery. But behind every “new” assay is a decade of design, failure, and rethinking. field 🧠 Designed for researchers at every career stage

trials derail. ✅ Practical strategies  for using receptor trafficking data and system set-points to design Every ligand you design enters a system that is already balancing opposing forces—vasoconstriction vs Reflexes as Drug Design Partners Not all reflexes are enemies. Some can make a mediocre drug shine. The teaser question How could you design your next lead to recruit the body’s own feedback loops in your This section raises a critical design question for teams Are you sure your “antagonist” is enough—or

The power of this design lies not in its independence but in its interdependence . And experiments are better designed because expectations are realistic. The most effective discovery programs are structured like Carlsson’s: modeling designed with downstream And he prioritizes shared purpose , designing each project with the next experiment in mind. GPCR Models Don’t Discover Drugs—People Do In GPCR research, the biggest breakthroughs won’t come from

They design assays differently. They interpret deviations differently. Kenakin  noted, it wasn’t designed. It was revealed only when the drug encountered the full complexity of the cardiovascular regulatory network Kenakin talked about  the specific allosteric properties orthosteric drugs cannot offer. GPCR innovation is accelerating, and those who invest in deeper GPCR pharmacology insights today will

In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold mechanisms shaping go/no-go choices Strategic insights into early identification and mitigation of drug clarifies that both direct hepatotoxic effects and conditional toxicities, such as those driven by drug-drug Red-flagging toxicophores accelerates rational design cycles Computational prediction complements biological As GPCR science and pharmacological innovation accelerate, timely guidance from foundational to advanced

GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. features a discussion about a scalable GPCR-RAMP assay. Their global resource is now helping labs decode GPCR biology at scale. It’s exciting to see how the GPCR field is evolving. GPCR Team

research and GPCR drug discovery. Community feedback is central to how this partnership is designed to work. GPCR. research and GPCR drug discovery. GPCR supports scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.

GPCR and global experts at the GPCR Drug Discovery session during Discovery on Target 2025—where groundbreaking GPCR Drug Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery Structure-based design  powered by cryo-EM and AI. 🔬 Inside the GPCR Track Agenda Expect deep dives design strategy. Let’s move GPCR drug discovery forward — together. 🚨 Mark your calendar for the GPCR Happy Hour Join

Drug Discovery Summit  is bringing together 80+ senior leaders across GPCR-focused biopharma from April empowers scientists to simplify complex workflows, accelerate discovery, and drive breakthroughs in drug Whether you're decoding signaling pathways or designing the next generation of therapeutics, Revvity biosensors and BacMam gene delivery tools to measure the spatial and temporal signaling properties of drug delivers kinetic profiles that reliably inform decisions and reduce the risk and cost of developing new drugs

Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. Meetings drag. Decisions stall. And momentum quietly dies. GPCR Ecosystem. Strong science. Promising data. But no systems to turn it into momentum. Here’s what I bring: Biology-First Strategy I’ve designed GPCR assays, led collaborations across research GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide.

Masterclass on GPCR Allostery: Unveiling Techniques to Decode Drug Behavior – July 31st, 2025. Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already Some drugs take hours to reach equilibrium—not because of poor design, but because the system is fluid Why you need to be there: Learn how kinetic nuance shapes ligand design.   lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—designed